Top Markets
Coin of the day
Cortexyme, Inc. Cortexyme, Inc.

Cortexyme, Inc.

CRTX
Rangering i aksjer #25179
Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to... Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to pioneering new therapies for Alzheimer's and various other degenerative conditions. The company's primary investigational drug, atuzaginstat (also known as COR388), is an orally delivered, small molecule inhibitor engineered to cross the blood-brain barrier and target gingipain. This compound is currently in Phase II/III clinical trials, where it is being assessed for its potential use in individuals with mild to moderate Alzheimer's disease, as well as for tackling oral squamous cell carcinoma, periodontitis, and coronavirus infections. Established in 2012, Cortexyme, Inc. is headquartered in South San Francisco, California.
Aksjekurs
$1.95
Sist synkronisert: 2022-07-29
Markedsverdi
$52.48M
Endring (1 dag)
2.63%
Endring (1 år)
0.00%
Land
US
Handel Cortexyme, Inc. (CRTX)

Kategori

P/B-forhold for Cortexyme, Inc. (CRTX)
P/B-forhold per 2026 TTM: 0
Ifølge Cortexyme, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Cortexyme, Inc. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
3.7087 -
US